The standoff between Anthropic and the Trump administration erupted in February when Amodei said he “cannot in good conscience accede” to the Pentagon’s demands for unrestricted use of Anthropic’s technology, including for fully autonomous weapons or widespread surveillance of Americans.
The refusal led the Trump administration to label Anthropic a “supply-chain risk,” a designation typically associated with national security threats, and prompted an order for federal agencies to stop using the Claude developer’s products. The move also effectively barred government defense contractors from doing business with Anthropic.
What followed was a months-long confrontation with the Trump administration that threatened Anthropic’s ability to grow its government business.
However, in her decision last Thursday, California federal judge Rita Lin rejected the administration’s national security justification for the move, writing that “the empty invocation of national security is not a blank check to punish and retaliate against government critics,” The New York Times reports.
Anthropic still isn’t out of the woods. The company faces a separate legal fight in a Washington appeals court, which previously rejected its request to pause the supply-chain designation, and the government could appeal the California ruling.
But as the Financial Times reported, Amodei isn’t backing away from the two “red lines” at the center of the dispute, even with potentially billions of dollars in revenue hanging in the balance.
The billion-dollar price of saying no
In March court filings, Anthropic chief financial officer Krishna Rao warned that the fallout could extend well beyond the company’s government business. With customers already questioning their relationships with Anthropic, Rao said the government’s actions could put hundreds of millions, or even billions, of dollars in revenue at risk.
Business Insider later crunched the numbers and estimated that the dispute could cost the Claude developer as much as $5 billion in lost business. This includes more than $150 million in direct defense contracts, a $100-million contract with the U.S. Food and Drug Administration (FDA) and as much as $180 million in potential business with financial institutions, according to court filings from Rao and Anthropic chief commercial officer Paul Smith, Reuters reports.
It was a cost Anthropic was apparently willing to bear. In his Feb. 26 statement, Amodei acknowledged that the company had previously sacrificed revenue for its principles, pointing to decisions made even when they ran counter to Anthropic’s immediate business goals.
“We have consistently acted to defend America’s lead in AI, even when it is against the company’s short-term interest,” Amodei said.
